Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesamorelin for Reducing Hepatic Steatosis in MASLD
NCT07481734Phase 2Recruiting
- Sponsor
- Hudson Biotech
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of tesamorelin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Hudson Biotech. Started Feb 2026; status: recruiting.
02
Drugs
tesamorelin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07481734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481734.